Mobia Medical (MOBI) 8th Annual Wolfe Research Healthcare Conference summary

Vivistim and unmet need

• Vivistim is a Class III implantable vagus nerve stimulator intended to improve hand and arm function through a six-week rehabilitation protocol.

• The addressable population includes 9 million U.S. ischemic stroke survivors living with impairments; early research found ~75% of survivors actively seek solutions.

• The stated ambition is to make stroke recovery part of comprehensive stroke-center care and establish Vivistim as standard of care.

Adoption and care delivery

• Awareness remains the main adoption challenge; clinicians, patients, families, and therapists need education, with a deliberate hospital-by-hospital rollout to build durable programs.

• AHA guideline inclusion is viewed as validation and is already influencing hospital and physician perceptions; practice change through quality measures and audits is expected to take more time.

• Hospital-system adoption has expanded from an individual hospital to an entire system; implementation relies on multidisciplinary teams, with stroke neurologists central to coordination and neurosurgeons performing the procedure.

• Territory managers develop hospital programs and early identification; OT/PT therapy development specialists support therapy sites, especially at the start and end of treatment.

• Patients can activate the device up to eight times daily at home; pivotal data showed continued improvement through two years, supported by daily-activity practice developed with therapists.

Clinical evidence and registry plans

• The VNS-REHAB pivotal trial is the clinical foundation; GRASP is intended to test generalizability across U.S. locations and demographics against pivotal-study endpoints and timelines.

• The first GRASP readout is planned for 2027, with a substantial patient cohort; the registry is intended to grow, with publications and readouts on a regular basis.

• The 2027 registry analysis is expected to build evidence rather than be definitive; larger numbers and longer follow-up are intended to deepen understanding across patient populations.